Vanta Bioscience
- Market cap
- ₹ 15 Cr.
- P/E
- 131.9x
- P/B
- 0.69x
- 52-week range
- 14.71 – 29
- ROE
- 1%
- ROCE
- 1.2%
- Dividend yield
- 0%
- Debt / equity
- 1.8
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- BSE SME
About
Vanta Bioscience Limited is an India-based preclinical contract research company. The Company provides services for testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research, and environmental studies. It offers a host of preclinical safety assessment services for clients from pharmaceuticals, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemical industries. Additionally, it provides risk assessment services to evaluate the safety of active pharmaceutical ingredients, excipients, extractables, leachable, and pharmaceutical impurities resulting from the manufacturing process or product degradation. The Company’s services include discovery toxicology, agro-chemical and chemical safety, biocompatibility studies, diet formulation, and batch release tests. The Company has investments in one of its subsidiaries, Vantaclinical Research Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Vanta Bioscience against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)131.9 against a typical 34.2: pricier than most peers (1st = cheapest).11th of 11
- Sales growth−57.5% against a typical +16.4% from a year earlier.10th of 10
- Share price, 3 months−19.3% against a typical −13%.10th of 11
- Size₹ 14.5 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).11th of 11
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 5 | 5 | 4 | 3 | 3 | 6 | 4 | 1 | 0 | 0 | 2 |
| Expenses | 4 | 3 | 4 | 2 | 3 | 5 | 4 | 4 | 1 | 2 | 1 | 0 |
| Operating Profit | 2 | 2 | 1 | 2 | −1 | −2 | 2 | −1 | −0 | −2 | −0 | 1 |
| OPM % | 33.7% | 45.8% | 27.7% | 45.9% | −19.5% | −53.6% | 33.3% | −21.1% | −37.9% | −509.1% | −123.3% | 91.4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 2 | −0 | 1 | −0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | −0 | 1 | −0 |
| Profit before tax | 0 | 0 | −0 | 1 | −4 | −6 | −2 | −7 | −4 | −1 | −2 | 2 |
| Tax % | 68.8% | 9.3% | −106.9% | 13.5% | 2.1% | 1.5% | −0.9% | −3.1% | −1.2% | −2.1% | −2.7% | −2.7% |
| Net Profit | 0 | 0 | 0 | 0 | −3 | −4 | −1 | −2 | −2 | −1 | −2 | 2 |
| EPS in Rs | 0.1 | 0.62 | 0.03 | 0.11 | −4.06 | −6.21 | −0.86 | −2.82 | −3.28 | −2.17 | −2.56 | 2.71 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- −29%
- 3 Years
- −32%
- TTM
- −7%
- 10 Years
- —
- 5 Years
- −24%
- 3 Years
- 26%
- TTM
- 102%
- 10 Years
- —
- 5 Years
- −31%
- 3 Years
- −21%
- TTM
- —
- 10 Years
- —
- 5 Years
- −15%
- 3 Years
- −16%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vanta Bioscience | ₹ 20.40 | ₹ 15 Cr. | 131.9x | 0.7x | 1% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 35.4x | 5.1x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 97x | 15.2x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72x | 19x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.4x | 4.3x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,08,738 Cr. | 124.1x | 20.9x | — | 15% |
Management
- Sadhanala Venkata Rao
- Chief Executive Officer, Whole Time Director
- Annabatula Kiran Kumar
- Chief Financial Officer
- Dopesh Raja Mulakala
- Managing Director, Director
Prices are delayed and for information only. Nothing on this page is investment advice.